Abstract
In 2009, the FDA approved extended-release guanfacine — an α2-adrenergic agonist — for treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD; JW Pediatr Adolesc Med Oct 7 2009). Now, the FDA has approved another α2-adrenergic agonist — extended-release clonidine hydrochloride (KAPVAY) — for use as monotherapy or as an adjunct to stimulants for treatment of ADHD in patients …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
